| 教員紹介トップページへ | 三重大学トップページへ |
| 職名 | 教授 | |||||||||
| 氏名 | 田丸 智巳 |
|||||||||
| 生年月 | ||||||||||
|
||||||||||
| TEL | ||||||||||
| FAX | ||||||||||
| 個人のホームページ | ||||||||||
| 学歴 | 三重大学医学部 学士課程 (～1998年)
三重大学大学院医学部 博士課程・博士後期課程 (～2006年) 満了 |
|||||||||
| 学位 | 2006.03 博士 三重大学
|
|||||||||
| 所属学会 | 日本内科学会 日本血液学会 日本臨床腫瘍学会 日本癌学会 日本癌治療学会 日本血栓止血学会 日本臨床薬理学会 日本乳癌学会 日本臨床試験学会 | |||||||||
| 社会活動 | ||||||||||
| 職歴 | 2017.04～2017.04 厚生労働省 医政局 研究開発振興課 医系技官 再生医療等研究推進室長補佐
2017.04～2017.07 厚生労働省 医政局 総務課 医系技官 課長補佐 2017.08～2018.03 厚生労働省 医政局 地域医療計画課 医系技官 課長補佐 2018.04～2019.03 三重県 医療保健部 医師 医療政策総括監 |
|||||||||
| 学術（芸術）賞 | ||||||||||
| 専門分野 | ||||||||||
| 現在の研究課題 | ||||||||||
| 担当科目 | ||||||||||
| 主な業績等 | Inhibition by Rho-kinase and protein kinase C of myosin phosphatase is involved in thrombin-induced shape change of megakaryocytic leukemia cell line UT-7/TPO. 2005.03 Cellular signalling 17 321-30
Rho-kinase induces association of adducin with the cytoskeleton in platelet activation. 2005.07 Biochemical and biophysical research communications 332 347-51 Calyculin A retraction of mature megakaryocytes proplatelets from embryonic stem cells. 2008.02 Biochemical and biophysical research communications 366 763-8 Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. 2009.01 Blood 113 1071-4 [Irinotecan as second-line chemotherapy for 5-FU-resistant gastric cancer with disseminated intravascular coagulation: a case report]. 2011.09 Gan to kagaku ryoho. Cancer & chemotherapy 38 1517-20 Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation. 2013 Circulation journal : official journal of the Japanese Circulation Society 77 1436-44 Difference in survival and prognostic factors between smokers and never-smokers with advanced non-small-cell lung cancer. 2013.02 International journal of clinical oncology 18 17-25 [A case report of a well-differentiated neuroendocrine tumor in which sunitinib treatment resulted in stable disease]. 2013.09 Gan to kagaku ryoho. Cancer & chemotherapy 40 1237-40 Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. 2015.08 International journal of hematology 102 188-94 A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity. 2016 Case reports in oncological medicine 2016 7510901- Colon cancer chemotherapy for a patient with CDX2-expressing metastatic thymic adenocarcinoma: a case report and literature review. 2016.04 International cancer conference journal 5 113-119 Successful treatment by prednisolone for interstitial pneumonia associated with anagrelide in a patient with essential thrombocythemia. 2017.01 International cancer conference journal 6 22-24 Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension. 2017.10 Journal of clinical hypertension (Greenwich, Conn.) 19 990-998 Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. 2018.03 Oncotarget 9 14909-14921 [A Case of Poorly Differentiated Carcinoma of Unknown Primary Site with Risk of Choriocarcinoma Syndrome Effectively Treated with Reduced Bleomycin,Cisplatin ,Etoposide Combination Regimen(BEP Regimen)]. 2018.04 Gan to kagaku ryoho. Cancer & chemotherapy 45 643-645 Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy. 2018.04 Clinical breast cancer 18 e157-e165 TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial. 2018.10 BMJ open 8 e020948- Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial. 2019.06 Journal of clinical medicine 8 DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study. 2019.10 Haematologica 105 DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. 2020.06 Haematologica 105 2308-2315 Risk factors for cisplatin-induced acute kidney injury: A pilot study on the usefulness of genetic variants for predicting nephrotoxicity in clinical practice. 2020.11 Molecular and clinical oncology 13 58- |
|||||||||